Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



MS Patients Need a Drug Therapy Without Awful Side Effects

Never having been offered, let alone received any disease modifying therapy, I can address the subject of disease modifying therapies, and their side effects, with complete impartiality. Of course, the reason for the lack of any medication is because none has yet been approved for use with MS patients who have the primary progressive type.

Let’s start by looking at the drug natalizumab and its relationship with progressive multifocal leukoencephalopathy (PM)L. Natalizumab, which goes by the brand name of Tysabri, has been the center of controversy and concern for years over whether patients on that therapy run the risk of developing PML. This is a life-threatening viral infection caused by the John Cunningham (JC) virus.

The reason that natalizumab has never been offered to me is that it is used to treat highly active relapsing-remitting MS (RRMS) in patients. However, it has been associated with the development of PML.

A previous news story on this site headlined “Guidelines Issued for Monitoring of MS Patients on Natalizumab Treatment” said: “Before the age of immunomodulating biological drugs, PML was associated with immunosuppression but not with autoimmune diseases such as MS. The JC virus is common and usually benign, and infects an estimated 60 percent of the European population. But the type causing PML is a mutated form that can enter into the brain, and researchers are puzzled as to why the virus mutates in MS patients on natalizumab.”

A panel of neurologists from the U.K. and Ireland was put together by pharmaceutical manufacturer Biogen, but worked independently of the company. Members did not receive any payment for their work.

MS patients have safety considered
They analyzed available data from clinical trials and real-life use. Their findings were published in the article “Stratification and monitoring of natalizumab associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group,” which appeared in the Journal of Neurology, Neurosurgery & Psychiatry.

So, it seems that with disease modifying drugs, because all DMTs are drugs, patients everywhere need to be aware not only of side effects information provided with the medication but also with others that may occur without warning.

I have been looking at the side effects of new MS drugs for some years now and have been generally disappointed by what has turned up.

Things like unsteadiness and fatigue — as if we don’t have enough already — are bad enough, but then we get to the rare ones. I cannot tell you how many times “death” has been listed.

But that’s ok as no one reads the patient information sheets, do they? Well, call me a nerd if you like but yes, I do. And, I have to say, that is one reason that no DMT has ever seemed attractive to my way of thinking.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Go to Newer News Go to Older News